乳腺癌临床病理特征及治疗的相关研究进展
摘要
子分型推动了乳腺癌治疗的个性化发展。新辅助治疗的应用提高了手术成功率和保乳率，同时为评估治疗反应提供了依据。
此外，基因组学及精准医学的进步，使得早期发现乳腺癌、避免复发和耐药成为可能。
关键词
全文:
PDF参考
[1] 秦梦霞,李思甜,李文爱,等.山西省女性乳
腺 癌 防 治 知 信 行 现 状 及 影 响 因 素 研 究 [J]. 中 国 健 康 教
育 ,2024,40(03):230-237.DOI:10.16168/j.cnki.issn.1002-
9982.2024.03.007.
[2] Burciu OM, Sas I, Merce AG, Cerbu S, Moatar AE,
Eftenoiu AE, Cobec IM. Comprehensive Analysis of Receptor
Status, Histopathological Classifications (B1-B5), and Cumulative
Histological Dimensions in Breast Cancer: Predictors of
Malignancy and Diagnostic Implications. Cancers (Basel). 2024
Oct 14;16(20):3471. doi: 10.3390/cancers16203471.
[3] Yunfang Yu et al., Development and validation of
novel microenvironment-based immune molecular subtypes of
breast cancer: Implications for immunotherapy.. JCO 37, 1094-
1094(2019).
[4] Chen X, Cai Q, Deng L, Chen M, Xu M, Chen L,
Lin Y, Li Y, Wang Y, Chen H, Liu S, Wu J, Tong X, Fu F,
Wang C. Association of inflammatory blood markers and
pathological complete response in HER2-positive breast cancer:
a retrospective single-center cohort study. Front Immunol. 2024
Nov 19;15:1465862. doi: 10.3389/fimmu.2024.1465862.
[5] Lee H S , Lee I H , Kang K ,et al.Network
Pharmacology-Based Dissection of the Comprehensive Molecular
Mechanisms of the Herbal Prescription FDY003 Against
Estrogen Receptor-Positive Breast Cancer[J].Natural Product
Communications, 2021.DOI:10.1177/1934578X211044377.
[6] Jang N, Choi JE, Kang SH, Bae YK. Validation of the
pathological prognostic staging system proposed in the revised
eighth edition of the AJCC staging manual in different molecular
subtypes of breast cancer. Virchows Arch. 2019 Feb;474(2):193-
200. doi: 10.1007/s00428-018-2495-x.
[7] Elsayed B, Alksas A, Shehata M, Mahmoud A, Zaky
M, Alghandour R, Abdelwahab K, Abdelkhalek M, Ghazal
M, Contractor S, El-Din Moustafa H, El-Baz A. Exploring
Neoadjuvant Chemotherapy, Predictive Models, Radiomic,
and Pathological Markers in Breast Cancer: A Comprehensive
Review. Cancers (Basel). 2023 Nov 4;15(21):5288. doi: 10.3390/
cancers15215288.
[8] Chen YZ, Xu S, Ren H, Zhang J, Jia Y, Sun H.
Characterization of novel sialylation-associated microRNA
signature for prognostic assessment in breast cancer and
its implications for the tumor microenvironment. J Steroid
Biochem Mol Biol. 2025 Feb 1;248:106683. doi: 10.1016/
j.jsbmb.2025.106683.
[9] Olsson E, Lindman H, Digkas E, Thurfjell V, Ali
HM, Krüger U, Wennstig AK, Sundqvist M, Valachis A.
Genomic characterization and molecular predictive biomarkers
for chemotherapy in patients with metastatic triple-negative
breast cancer treated in a real-world setting. Breast. 2025
Feb;79:103874. doi: 10.1016/j.breast.2025.103874.
[10] Yang X, Yang D, Qi X, Luo X, Zhang G. Endocrine
treatment mechanisms in triple-positive breast cancer: from
targeted therapies to advances in precision medicine. Front Oncol.
2025 Jan 7;14:1467033. doi: 10.3389/fonc.2024.1467033.
[11] Książek P, Muzyka M, Nadzieja-Kozioł A, Dziadek
K, Pruszko C. PD208 Optimal Scheme For Molecular Diagnosis
Of BRCA1/2 Gene Mutations In Patients With Breast Cancer
In Poland - Cost-Utility Analysis. International Journal of
Technology Assessment in Health Care. 2024;40(S1):S173-S173.
doi:10.1017/S0266462324004306.
[12] Araya C, Mino B, Le Cerf P, Gaete F, Armisen R,
Carvajal-Hausdorf DE. Molecular Analysis of PIK3CA in
Metastatic Hormone Receptor-Positive Breast Cancer in Chile:
Clinical and Pathological Insights. Int J Mol Sci. 2024 Nov
14;25(22):12246. doi: 10.3390/ijms252212246.
[13] Mahendran G, Shangaradas AD, Romero-Moreno R,
Wickramarachchige Dona N, Sarasija SHGS, Perera S, Silva GN.
Unlocking the epigenetic code: new insights into triple-negative
breast cancer. Front Oncol. 2024 Dec 18;14:1499950. doi:
10.3389/fonc.2024.1499950.
[14] Yang M, Guo J, Li J, Wang S, Sun Y, Liu Y, Peng
Y. Platycodon grandiflorum-derived extracellular vesicles
suppress triple-negative breast cancer growth by reversing the
immunosuppressive tumor microenvironment and modulating the
gut microbiota. J Nanobiotechnology. 2025 Feb 7;23(1):92. doi:
10.1186/s12951-025-03139-x.
[15] Traub L, Thill M, Nitschmann S. 20-Jahres-Ergebnisse
einer 5jährigen Hormontherapie bei Mammakarzinom : Early
Breast Cancer Trialists’ Collaborative Group (EBCTCG) [The
20-year results of 5year hormone therapy in breast cancer :
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)].
Internist (Berl). 2018 Apr;59(4):410-412. German. doi: 10.1007/
s00108-018-0398-1.
[16] Yoshitake R, Mori H, Ha D, Wu X, Wang J, Wang X,
Saeki K, Chang G, Shim HJ, Chan Y, Chen S. Molecular features
of luminal breast cancer defined through spatial and single-cell
transcriptomics. Clin Transl Med. 2024 Jan;14(1):e1548. doi:
10.1002/ctm2.1548.
[17] Li X, Zhang X, Yin S, Nie J. Challenges and prospects
in HER2-positive breast cancer-targeted therapy. Crit Rev
Oncol Hematol. 2025 Jan 16;207:104624. doi: 10.1016/
j.critrevonc.2025.104624. Epub ahead of print.
[18] Yüceer RO, Aydın S, Gelir I, Koc T, Tuncer E,
Ucar M. Exploring the Prognostic Role of Trop-2, CD47, and
CD163 Expression Levels on Survival Outcomes in Patients with
Triple-Negative Breast Cancer. Diagnostics (Basel). 2025 Jan
20;15(2):232. doi: 10.3390/diagnostics15020232.
[19] Jain A, Barge A, Parris CN. Combination strategies
with PARP inhibitors in BRCA-mutated triple-negative breast
cancer: overcoming resistance mechanisms. Oncogene. 2025
Feb;44(4):193-207. doi: 10.1038/s41388-024-03227-6.
[20] Mallick S, Duttaroy AK, Dutta S. The PIK3CA gene
and its pivotal role in tumor tropism of triple-negative breast
cancer. Transl Oncol. 2024 Dec;50:102140. doi: 10.1016/
j.tranon.2024.102140.
[21] Nicolò E, Gianni C, Curigliano G, Reduzzi C,
Cristofanilli M. Modeling the management of patients with
human epidermal growth factor receptor 2-positive breast
cancer with liquid biopsy: the future of precision medicine.
Curr Opin Oncol. 2024 Nov 1;36(6):503-513. doi: 10.1097/
CCO.0000000000001082.
[22] Fang D, Zhou Y, Liao F, Lu B, Li Y, Lv M, Luo Z, Ma
Y. Identification and characterization of cuproptosis related gene
subtypes through multi-omics bioinformatics analysis in breast
cancer. Discov Oncol. 2025 Feb 13;16(1):171. doi: 10.1007/
s12672-025-01952-2.
[23] Tang L, Wang D, Hu T, Lin X, Wu S. Current
applications of tumor local ablation (TLA) combined with immune
checkpoint inhibitors in breast cancer treatment. Cancer Drug
Resist. 2024 Sep 13;7:33. doi: 10.20517/cdr.2024.77. [24]Song
Q, Wang Y, Liu S. Subtype-specific transcription factors affect
polyamine metabolism and the tumor microenvironment in breast
cancer. Cancer Innov. 2024 Dec 2;4(1):e138. doi: 10.1002/
cai2.138.
[24] Montagna G. Estimating the Benefit of Preoperative
Systemic Therapy to Reduce the Extent of Breast Cancer Surgery:
Current Standard and Future Directions. Cancer Treat Res.
2023;188:149-174. doi: 10.1007/978-3-031-33602-7_6.
[25] Cavalcante FP, Millen EC, Novita GG, Zerwes FP,
Mattar A, Machado RHS, Frasson AL. Sentinel lymph node biopsy
following neoadjuvant chemotherapy: an evidence-based review
and recommendations for current practice. Chin Clin Oncol. 2023
Feb;12(1):6. doi: 10.21037/cco-22-110.
[26] Li K, Chadha M, Moshier E, Rosenstein BS; REQUITE
consortium. Age-stratified analysis of health-related quality of
life in patients with early-stage breast cancer receiving adjuvant
radiation therapy and endocrine therapy. J Geriatr Oncol. 2025
Feb 6;16(2):102195. doi: 10.1016/j.jgo.2025.102195.
[27] Bijarpasi F M , Sadremomtaz A .Evaluation of proton
therapy dose in breast cancer with boron agent based on GATE
Monte Carlo code[J].Journal of Radiation Research and Applied
Sciences[2025-02-23].DOI:10.1016/j.jrras.2025.101311.
[28] Ma T, Hao XM, Chen HD, Zheng MH, Chen XG, Cai
SL, Zhang J. Predictive markers of rapid disease progression and
chemotherapy resistance in triple-negative breast cancer patients
following postoperative adjuvant therapy. Sci Rep. 2025 Jan
2;15(1):386. doi: 10.1038/s41598-024-84785-3.
[29] Hulsbergen A, Broekman M, Smith T, Iorgulescu B.
74. EFFICACY OF HER2-TARGETED THERAPY IN HER2-
POSITIVE BREAST CANCER BRAIN METASTASES: A
NATIONAL ANALYSIS. Neurooncol Adv. 2020;2(Suppl 2):ii15-
ii16. Published 2020 Aug 4. doi:10.1093/noajnl/vdaa073.061.
[30] Sirek T, Król-Jatręga K, Borawski P, Zmarzły
N, Boroń D, Ossowski P, Nowotny-Czupryna O, Boroń K,
Janiszewska-Bil D, Mitka-Krysiak E, Grabarek BO. Distinct
mRNA expression profiles and miRNA regulators of the PI3K/
AKT/mTOR pathway in breast cancer: insights into tumor
progression and therapeutic targets. Front Oncol. 2025 Jan
9;14:1515387. doi: 10.3389/fonc.2024.1515387.
[31] Li G, Du R, Wang D, Zhang X, Wang L, Pu S, Li X,
Wang S, Zhang J, Liu B, Gao Y, Zhao H. Improved Efficacy of
Triple-Negative Breast Cancer Immunotherapy via Hydrogel_xfffe_Based Co-Delivery of CAR-T Cells and Mitophagy Agonist.
Adv Sci (Weinh). 2025 Jan 22:e2409835. doi: 10.1002/
advs.202409835.
[32] Benyettou F, Khair M, Prakasam T, Varghese S,
Matouk Z, Alkaabi M, Pena-Sánchez P, Boitet M, AbdulHalim
R, Sharma SK, Ghemrawi R, Thomas S, Whelan J, Pasricha R,
Jagannathan R, Gándara F, Trabolsi A. cRGD-Peptide Modified
Covalent Organic Frameworks for Precision Chemotherapy in
Triple-Negative Breast Cancer. ACS Appl Mater Interfaces. 2024
Oct 23;16(42):56676-56695. doi: 10.1021/acsami.4c10812.
[33] Chen, J., Huang, J. Sorafenib delivered by cancer
cell membrane remodels tumor microenvironment to enhances
the immunotherapy of mitoxantrone in breast cancer. Journal
of Materials Research 35, 3296–3303 (2020). https://doi.
org/10.1557/jmr.2020.321.
[34] Jain A, Barge A, Parris CN. Combination strategies
with PARP inhibitors in BRCA-mutated triple-negative breast
cancer: overcoming resistance mechanisms. Oncogene. 2025
Feb;44(4):193-207. doi: 10.1038/s41388-024-03227-6.
[35] Menyhárt O, Győrffy B. Multi-omics approaches in
cancer research with applications in tumor subtyping, prognosis,
and diagnosis. Comput Struct Biotechnol J. 2021 Jan 22;19:949-
960. doi: 10.1016/j.csbj.2021.01.009.
(16 摘要 Views, 12 PDF Downloads)
Refbacks
- 当前没有refback。